ComBaCaL T2D: Community-based, eHealth Supported Type 2 Diabetes Care by Lay Village Health Workers in Rural Lesotho
Study Details
Study Description
Brief Summary
This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for the investigation of chronic diseases and their management in rural Lesotho that is maintained by local lay chronic care village health workers (CC-VHWs).
The overall objective of the ComBaCaL cohort study and nested TwiCs is to assess the impact of eHealthsupported, lay-led chronic disease control measures in rural Lesotho.
In this T2D TwiC, the effect, safety and feasibility of a community-based T2D care package (which includes the offer of first-line oral antidiabetic and lipid-lowering treatment for uncomplicated T2D by lay CC-VHWs in comparison to facility-based care after community-based screening and diagnosis) will be evaluated.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
N/A |
Detailed Description
Globally, 9.3% of the adult population or 436 million individuals were estimated to be living with diabetes in 2019. Until 2045 this number is expected to increase by more than 50% to over 700 million. Four out of five people affected by diabetes are currently living in low- and middle-income countries (LMICs). Over 90% of all diabetes cases are due to type 2 diabetes (T2D) which is also the main driver of the projected increase in overall diabetes cases. The increase in T2D prevalence is caused by ageing populations and changing lifestyles with decreasing levels of physical activity and higher caloric diets and associated obesity.
This cluster-randomized intervention is embedded in the ComBaCaL (Community-Based Chronic disease care Lesotho) cohort study (EKNZ ID AO_2022-00058, clinicaltrials.gov ID NCT05596773, Lesotho NH-REC ID 210-2022), a platform for the investigation of chronic diseases and their management in rural Lesotho that is maintained by local lay chronic care village health workers (CC-VHWs).
In this trial, using the Trials within Cohorts (TwiCs) approach, it will be analyzed whether an LHW-led model could be capacitated to safely and effectively provide first-line management (including oral antidiabetic, lipid-lowering treatment and lifestyle counselling) at community-level.
In villages randomized to the intervention arm, lay Chronic Care Village Health Workers (CCVHWs) operating within the existing Ministry of Health (MoH) village health worker system will be capacitated to screen for and diagnose T2D, to provide lifestyle counselling, to prescribe and to monitor first-line antidiabetic and lipid-lowering treatment for uncomplicated T2D and to provide treatment support for complicated T2D, supported by a tailored clinical decision support application (ComBaCaL app) in their villages.
The control group consists of people diagnosed with T2D living in villages that are also part of the ComBaCaL cohort but not sampled for the intervention (control villages), where CC-VHWs will only screen for and diagnose T2D with subsequent standardized counselling and referral to the closest health facility if T2D is present, but no village-based prescriptions. The overall objective of the ComBaCaL cohort study and nested TwiCs is to assess the impact of eHealthsupported, lay-led chronic disease control measures in rural Lesotho.
Study Design
Arms and Interventions
| Arm | Intervention/Treatment |
|---|---|
| Active Comparator: Intervention villages In the intervention villages, CC-VHWs will offer a T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level according to clinical algorithms based on international guidelines for primary healthcare management of T2D and the updated Lesotho Standard Treatment Guidelines. Direct guidance for treatment initiation, drug prescription, counselling and monitoring will be provided via the ComBaCaL app. In case of complicated disease (i.e. if treatment targets are not reached with metformin alone), unclear diagnosis, relevant comorbidities or presence of clinical alarm signs or symptoms, participants will be referred to the closest health facility for further management. |
Other: T2D care package
T2D care package including lifestyle counselling, firstline antidiabetic (metformin) and lipid-lowering (statin) treatment for uncomplicated T2D and treatment support and regular check-ups for complicated T2D at village-level. Guidance will be provided via the ComBaCaL app. In case of complicated disease referral to the closest health facility for further management.
|
| Active Comparator: Control villages In control villages, CC-VHWs will refer participants to the responsible health facility for therapeutic management after enrolment and baseline assessment. |
Other: Referral to the responsible health facility
CC-VHWs will refer participants to the responsible health facility for therapeutic management. The ComBaCaL app supports clinical decision making and documentation for screening, diagnosis and referral, but not prescription/provision and monitoring of antidiabetic or lipid-lowering medication for uncomplicated T2D patients or treatment support for complicated T2D patients.
|
Outcome Measures
Primary Outcome Measures
- Mean HbA1c (in percent) [12 months after enrolment]
Mean HbA1c (in percent)
Secondary Outcome Measures
- Change in 10-year CVD risk estimated [6 and 12 months after enrolment]
Change in 10-year CVD risk estimated using the World Health Organization (WHO) CVD risk prediction tool
- Mean HbA1c (in percent) [6 months after enrolment]
Mean HbA1c (in percent)
- Change in mean fasting blood glucose (FBG) (mmol/l) [6 and 12 months after enrolment]
Change in mean fasting blood glucose (FBG) (mmol/l)
- Change in proportion of participants with an HbA1c below 8% [6 and 12 months after enrolment]
Change in proportion of participants with an HbA1c below 8%
- Change in proportion of participants with an FBG below 7 mmol/l [6 and 12 months after enrolment]
Change in proportion of participants with an FBG below 7 mmol/l
- Change in number of CVD risk factors [6 and 12 months after enrolment]
Change in number of CVD risk factors (such as smoking status, BMI, abdominal circumference, blood lipid status, blood pressure, dietary habits and physical activity)
- Linkage to care: Change in proportion of participants not taking treatment at enrolment who have initiated pharmacological antidiabetic treatment [6 and 12 months after enrolment]
Change in proportion of participants not taking treatment at enrolment who have initiated pharmacological antidiabetic treatment
- Engagement in care: Change in proportion of participants who are engaged in care [6 and 12 months after enrolment]
Change in proportion of participants who are engaged in care, defined as reporting intake of antidiabetic medication as per prescription of a healthcare provider or reaching treatment targets without intake of medication
- Change in self-reported adherence to antidiabetic medication [6 and 12 months after enrolment]
Change in self-reported adherence to antidiabetic medication
- Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs) [within 6 and 12 months after enrolment]
Occurrence of Serious Adverse Events (SAEs) and Adverse Events of Special Interest (AESIs)
Other Outcome Measures
- Number of consultations (at a health facility and with the CC-VHW) [within 6 and 12 months after enrolment]
Number of consultations at a health facility and with the CC-VHW
- Trajectory of participants between facility-based and community-based care in the intervention villages [during the study period (up to 12 months)]
Trajectory of participants between facility-based and community-based care in the intervention villages (i.e. number of participants accepting community-based care at baseline, number of people switching to facility-based care and back to community-based care
- Proportion of participants with T2D who stop drug treatment or interrupt drug treatment for more than three weeks or require a switch of drug treatment due to (perceived) adverse events (AEs) [within 6 and 12 months after enrolment]
Proportion of participants with T2D who stop drug treatment or interrupt drug treatment for more than three weeks or require a switch of drug treatment due to (perceived) adverse events (AEs)
- Change in proportion of participants who are reaching treatment targets (FBG <7 mmol/l) and are reporting no intake of antidiabetic medication in the two weeks prior to assessment [6 and 12 months after enrolment]
Change in proportion of participants who are reaching treatment targets (FBG <7 mmol/l) and are reporting no intake of antidiabetic medication in the two weeks prior to assessment
- Change in proportion of participants accessing lipid-lowering medication [6 and 12 months after enrolment]
Change in proportion of participants accessing lipid-lowering medication
- Change in health system costs for the management of participants condition [within 6 and 12 months after diagnosis]
Change in health system costs for the management of participants condition
- Change in individual costs for participants for the management of their condition [within 6 and 12 months after diagnosis]
Change in individual costs for participants for the management of their condition
- Change in10-year CVD risk estimated using the Globorisk score [6 and 12 months after enrolment]
Change in10-year CVD risk estimated using the Globorisk score, a cardiovascular disease risk score that predicts risk of heart attack or stroke in healthy individuals for all countries in the world. It uses information on a person's country of residence, age, sex, smoking, diabetes, blood pressure and cholesterol to predict the chance that they would have a heart attack or stroke in the next 10 years.
- Change in10-year CVD risk estimated using the Framingham Risk Score [6 and 12 months after enrolment]
Change in10-year CVD risk estimated using the Framingham Risk Score, a sex-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. The Framingham Risk Score was first developed based on data obtained from the Framingham Heart Study.
- Quality of life (QOL) using the EQ-5D-5L instrument [12 months after enrolment]
The EQ-5D-5L is a self-assessed, health related, quality of life questionnaire. The scale measures quality of life on a 5-component scale including mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. The QOL scores are summed so that a higher score indicates higher quality of life.
- Health beliefs using the Beliefs about Medicines Questionnaire (BMQ) adapted for people living with T2D [12 months after enrolment]
The BMQl comprises two 4-item factors assessing beliefs that medicines are harmful, addictive, poisons which should not be taken continuously and that medicines are overused by doctors.The items are scored on a 5 point Likert scale with scores ranging from 4 to 20.
- Diabetes distress using the five item version of the "Problem Areas in Diabetes" (PAID-5) scale Problem Areas in Diabetes Scale-Five-item Short Form [12 months after enrolment]
Problem Areas in Diabetes Scale-Five-item Short Form. Total scores on the PAID-5 can range from 0 to 20, with higher scores suggesting greater diabetes-related emotional distress.
- Change in dosage of antidiabetic medications prescribed by CC-VHWs or healthcare professionals [6 and 12 months after enrolment]
Change in dosage of antidiabetic medications prescribed by CC-VHWs or healthcare professionals
- Change in dosage of lipid-lowering medications prescribed by CC-VHWs or healthcare professionals [6 and 12 months after enrolment]
Change in dosage of lipid-lowering medications prescribed by CC-VHWs or healthcare professionals
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Participant of the ComBaCaL cohort study (signed informed consent available)
-
Living with T2D, defined as reporting intake of antidiabetic medication or being newly diagnosed during screening via standard diagnostic algorithm
Exclusion Criteria:
-
Known type 1 diabetes mellitus
-
Reported pregnancy
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | SolidarMed Lesotho | Maseru | Lesotho | ||
| 2 | University of Basel, Division of Clinical Epidemiology | Basel | Switzerland | 4051 |
Sponsors and Collaborators
- University Hospital, Basel, Switzerland
- Swiss Agency for Development and Cooperation (SDC)
- World Diabetes Foundation (WDF)
- SolidarMed
Investigators
- Principal Investigator: Niklaus Labhardt, Prof., Division of Clinical Epidemiology, University Hospital Basel
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- AO_2022-00077; am23Labhardt